TEPADINA 15 mg powder for concentrate for solution for infusion, Trecondi 5 g powder for solution for infusion, Mozobil 20 mg/ml solution for injection, Trecondi 5 g powder for solution for infusion, Trecondi 1 g powder for solution for infusion, Trecondi 1 g powder for solution for infusion, Autologous haematopoietic stem and progenitor cell population containing CD34+ cells transduced with a lentiviral vector encoding the TCIRG1 cDNA ex vivo expanded.
Phase 2 small_molecule active
Quick answer
TEPADINA 15 mg powder for concentrate for solution for infusion, Trecondi 5 g powder for solution for infusion, Mozobil 20 mg/ml solution for injection, Trecondi 5 g powder for solution for infusion, Trecondi 1 g powder for solution for infusion, Trecondi 1 g powder for solution for infusion, Autologous haematopoietic stem and progenitor cell population containing CD34+ cells transduced with a lentiviral vector encoding the TCIRG1 cDNA ex vivo expanded. for Autosomal recessive osteopetrosis caused by mutations in the TCIRG1 gene is a Phase 2 program (small_molecule) at Fondazione Telethon ETS with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Fondazione Telethon ETS
- Indication
- Autosomal recessive osteopetrosis caused by mutations in the TCIRG1 gene
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active